Jpmorgan Chase & CO Atossa Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 118,929 shares of ATOS stock, worth $118,929. This represents 0.0% of its overall portfolio holdings.
Number of Shares
118,929
Previous 361,296
67.08%
Holding current value
$118,929
Previous $339,000
76.7%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ATOS
# of Institutions
86Shares Held
28.6MCall Options Held
12.7KPut Options Held
92.9K-
Black Rock Inc. New York, NY9.2MShares$9.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.83MShares$5.83 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN2.97MShares$2.97 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.05MShares$2.05 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.81MShares$1.81 Million0.0% of portfolio
About ATOSSA THERAPEUTICS, INC.
- Ticker ATOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,624,000
- Market Cap $127M
- Description
- Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...